Ind-Swift Laboratories Limited (INDSWFTLAB.NS)
INR 105.01
(-1.58%)
INR 105.01
(-1.58%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.13 Billion INR | -25.09% |
| 2022 | 5.51 Billion INR | 28.91% |
| 2021 | 4.28 Billion INR | 18.53% |
| 2020 | 3.61 Billion INR | 17.89% |
| 2019 | 3.06 Billion INR | 6.04% |
| 2018 | 2.88 Billion INR | -0.94% |
| 2017 | 2.91 Billion INR | 17.44% |
| 2016 | 2.48 Billion INR | -0.84% |
| 2015 | 2.5 Billion INR | 26.39% |
| 2014 | 1.98 Billion INR | 26.45% |
| 2013 | 1.56 Billion INR | -11.73% |
| 2012 | 1.77 Billion INR | -38.43% |
| 2011 | 2.88 Billion INR | 24.08% |
| 2010 | 2.32 Billion INR | 31.07% |
| 2009 | 1.77 Billion INR | 7.6% |
| 2008 | 1.64 Billion INR | 31.72% |
| 2007 | 1.25 Billion INR | 31.16% |
| 2006 | 953.4 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -4.81 Million INR | -101.7% |
| 2023 Q2 | 1.45 Billion INR | -1.9% |
| 2023 Q1 | 1.48 Billion INR | 4.4% |
| 2023 FY | 4.13 Billion INR | -25.09% |
| 2023 Q4 | 282.74 Million INR | -78.59% |
| 2023 Q3 | 1.32 Billion INR | -9.07% |
| 2022 Q3 | 1.3 Billion INR | -9.41% |
| 2022 Q1 | 1.36 Billion INR | 278.16% |
| 2022 FY | 5.51 Billion INR | 28.91% |
| 2022 Q4 | 1.41 Billion INR | 9.02% |
| 2022 Q2 | 1.43 Billion INR | 5.46% |
| 2021 Q2 | 1.3 Billion INR | 4.48% |
| 2021 FY | 4.28 Billion INR | 18.53% |
| 2021 Q1 | 1.25 Billion INR | 395.03% |
| 2021 Q3 | 1.35 Billion INR | 3.94% |
| 2021 Q4 | 360.12 Million INR | -73.51% |
| 2020 Q1 | 998.18 Million INR | 179.09% |
| 2020 FY | 3.61 Billion INR | 17.89% |
| 2020 Q4 | 252.93 Million INR | -77.74% |
| 2020 Q3 | 1.13 Billion INR | -7.14% |
| 2020 Q2 | 1.22 Billion INR | 22.58% |
| 2019 Q3 | 962.53 Million INR | 11.83% |
| 2019 FY | 3.06 Billion INR | 6.04% |
| 2019 Q1 | 882.19 Million INR | 490.14% |
| 2019 Q2 | 860.71 Million INR | -2.43% |
| 2019 Q4 | 357.65 Million INR | -62.84% |
| 2018 Q3 | 905.53 Million INR | 4.51% |
| 2018 FY | 2.88 Billion INR | -0.94% |
| 2018 Q4 | 149.48 Million INR | -83.49% |
| 2018 Q2 | 866.45 Million INR | -10.11% |
| 2018 Q1 | 963.91 Million INR | 0.0% |
| 2017 FY | 2.91 Billion INR | 17.44% |
| 2016 FY | 2.48 Billion INR | -0.84% |
| 2015 FY | 2.5 Billion INR | 26.39% |
| 2014 FY | 1.98 Billion INR | 26.45% |
| 2013 FY | 1.56 Billion INR | -11.73% |
| 2012 Q4 | 285.82 Million INR | -61.76% |
| 2012 Q3 | 747.44 Million INR | 40.15% |
| 2012 Q1 | 218.27 Million INR | 0.0% |
| 2012 Q2 | 533.32 Million INR | 144.33% |
| 2012 FY | 1.77 Billion INR | -38.43% |
| 2011 FY | 2.88 Billion INR | 24.08% |
| 2010 FY | 2.32 Billion INR | 31.07% |
| 2009 FY | 1.77 Billion INR | 7.6% |
| 2008 FY | 1.64 Billion INR | 31.72% |
| 2007 FY | 1.25 Billion INR | 31.16% |
| 2006 FY | 953.4 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sigachi Industries Limited | 2 Billion INR | -106.425% |
| Ind-Swift Limited | 2.17 Billion INR | -90.249% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -180.826% |
| Sakar Healthcare Limited | 699.58 Million INR | -490.81% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 96.227% |
| Innova Captab Limited | 3.46 Billion INR | -19.304% |
| Divi's Laboratories Limited | 32.44 Billion INR | 87.259% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 33.578% |
| Morepen Laboratories Limited | 6.16 Billion INR | 32.916% |
| Mankind Pharma Limited | 42.19 Billion INR | 90.205% |
| Sequent Scientific Limited | 2.97 Billion INR | -38.758% |
| Wanbury Limited | 1.73 Billion INR | -138.826% |
| Laurus Labs Limited | 15.44 Billion INR | 73.246% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 14.307% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 66.756% |
| Alembic Limited | 1 Billion INR | -313.277% |
| Hikal Limited | 5.95 Billion INR | 30.627% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 84.566% |
| Neuland Laboratories Limited | 8.24 Billion INR | 49.887% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 72.913% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 94.039% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 12.415% |
| Themis Medicare Limited | 2.42 Billion INR | -70.794% |
| RPG Life Sciences Limited | 2.48 Billion INR | -66.461% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 96.699% |
| Lupin Limited | 125.09 Billion INR | 96.696% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -97.38% |
| Wockhardt Limited | 7.72 Billion INR | 46.461% |
| Vaishali Pharma Limited | 90.32 Million INR | -4476.04% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 29.121% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -533.356% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 78.958% |
| FDC Limited | 6.58 Billion INR | 37.244% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 97.474% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -566.135% |
| Eris Lifesciences Limited | 10.42 Billion INR | 60.36% |
| Venus Remedies Limited | 2.18 Billion INR | -89.373% |
| ZIM Laboratories Limited | 1.26 Billion INR | -226.012% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -11.847% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -681.126% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 55.105% |
| Shilpa Medicare Limited | 3.56 Billion INR | -16.04% |
| Albert David Limited | 1.4 Billion INR | -193.534% |
| Ajanta Pharma Limited | 21.06 Billion INR | 80.378% |
| Hester Biosciences Limited | 1.27 Billion INR | -224.517% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -0.241% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 349.605% |
| Gufic Biosciences Limited | 4.07 Billion INR | -1.46% |
| Windlas Biotech Limited | 1.33 Billion INR | -208.726% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 28.508% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -3556.776% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | -497.983% |
| Granules India Limited | 16.79 Billion INR | 75.396% |
| Aarti Drugs Limited | 8.31 Billion INR | 50.299% |
| Bal Pharma Limited | 770.19 Million INR | -436.646% |
| Alkem Laboratories Limited | 52.29 Billion INR | 92.097% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 98.401% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | -119.052% |
| Medicamen Biotech Limited | 495.49 Million INR | -734.159% |
| Unichem Laboratories Limited | 4.86 Billion INR | 15.041% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -814.119% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -32847.126% |
| Valiant Laboratories Limited | 138.02 Million INR | -2894.456% |
| Orchid Pharma Limited | 2.32 Billion INR | -78.133% |
| Medico Remedies Limited | 262.14 Million INR | -1476.697% |
| Ipca Laboratories Limited | 48.58 Billion INR | 91.493% |
| Brooks Laboratories Limited | 65.62 Million INR | -6198.715% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -638.73% |
| Piramal Enterprises Limited | 8.04 Billion INR | 48.613% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 91.16% |
| NATCO Pharma Limited | 25.73 Billion INR | 83.94% |
| Suven Life Sciences Limited | -200.79 Million INR | 2158.406% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 3900.764% |
| Strides Pharma Science Limited | 14.38 Billion INR | 71.273% |
| Indoco Remedies Limited | 8.04 Billion INR | 48.611% |
| Alpa Laboratories Limited | 188.89 Million INR | -2088.103% |
| Lasa Supergenerics Limited | 121.02 Million INR | -3315.035% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -956.91% |